Scarica l'app Stockscreener
24.16
4.45%
1.03
Pre-mercato:
24.17
0.01
+0.04%
Precedente Chiudi:
$23.13
Aprire:
$23.15
Volume 24 ore:
1.08M
Relative Volume:
0.98
Capitalizzazione di mercato:
$1.64B
Reddito:
$2.74B
Utile/perdita netta:
$-441.40M
Rapporto P/E:
-3.6942
EPS:
-6.54
Flusso di cassa netto:
$13.00M
1 W Prestazione:
-16.11%
1M Prestazione:
-27.23%
6M Prestazione:
-6.43%
1 anno Prestazione:
-41.77%
Intervallo 1D:
$23.15
$24.75
Intervallo di 1 settimana:
$21.65
$27.04
Portata 52W:
$19.50
$42.50
Quidelortho Corporation Stock (QDEL) Company Profile
Nome
Quidelortho Corporation
Settore
Industria
Telefono
(858) 552-1100
Indirizzo
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
24.16 | 1.57B | 2.74B | -441.40M | 13.00M | -6.54 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-07 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-10 | Iniziato | Jefferies | Hold |
| 2024-09-19 | Ripresa | UBS | Neutral |
| 2024-09-05 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2024-03-04 | Downgrade | UBS | Neutral → Sell |
| 2024-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-14 | Aggiornamento | UBS | Sell → Neutral |
| 2022-09-19 | Iniziato | Citigroup | Neutral |
| 2022-07-20 | Iniziato | UBS | Sell |
| 2022-06-17 | Ripresa | JP Morgan | Neutral |
| 2022-02-22 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Ripresa | Raymond James | Strong Buy |
| 2018-03-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Reiterato | Barclays | Overweight |
| 2018-01-04 | Aggiornamento | CL King | Neutral → Buy |
| 2017-09-19 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Reiterato | Canaccord Genuity | Hold |
| 2017-02-17 | Iniziato | CL King | Neutral |
| 2016-12-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Reiterato | Barclays | Overweight |
| 2016-02-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Reiterato | Canaccord Genuity | Buy |
| 2015-12-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Iniziato | Barclays | Overweight |
| 2013-07-31 | Reiterato | Canaccord Genuity | Buy |
| 2011-03-03 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Quidelortho Corporation Borsa (QDEL) Ultime notizie
QuidelOrtho Corp SEC 10-K Report - TradingView
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference - marketscreener.com
The Top 5 Analyst Questions From QuidelOrtho's Q4 Earnings Call - Finviz
QuidelOrtho and Lifotronic agree on global immunoassay portfolio expansion - MSN
QuidelOrtho Partnership Targets Expanded Immunoassay Reach in International Markets - TipRanks
QuidelOrtho–Lifotronic Partnership Targets Global Immunoassay Expansion - TipRanks
QuidelOrtho–Lifotronic Partnership Targets Immunoassay Expansion in International Markets - TipRanks
Surprises Report: Is QuidelOrtho Corporation a turnaround storyMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
The Top 5 Analyst Questions From QuidelOrtho’s Q4 Earnings Call - Yahoo Finance
QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2025 earnings call transcript - MSN
QuidelOrtho Expands Global Immunoassay Offering Through Lifotronic Partnership - TipRanks
QuidelOrtho Corporation (QDEL): Analyzing Its 47% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio - Il Giornale dei Castelli Romani
QuidelOrtho enters strategic supply agreement to expand global immunoassay portfolio - BioSpectrum Asia
QuidelOrtho Enters Strategic Supply Agreement with Lifotronic - Intellectia AI
QuidelOrtho Q4 results beat on both lines, but issues weak 2026 EPS guidance - MSN
Will QuidelOrtho Corporation be affected by tariffsJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
QuidelOrtho Announces Planned Retirement of Chief Financial Officer - The Globe and Mail
QuidelOrtho Earnings Call: Growth, Margins And Risks - TipRanks
QuidelOrtho Corporation (NASDAQ:QDEL) Just Reported, And Analysts Assigned A US$34.67 Price Target - 富途牛牛
QuidelOrtho Corporation (NASDAQ:QDEL) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
Top QuidelOrtho Insiders Make Bold Move With Fresh Share Purchases - TipRanks
A Look At QuidelOrtho (QDEL) Valuation After Earnings Update And CFO Transition News - Sahm
Insider Buying: QuidelOrtho (NASDAQ:QDEL) Director Acquires 10,000 Shares of Stock - MarketBeat
QuidelOrtho CFO Busky buys $79k in shares By Investing.com - Investing.com Australia
Joseph Busky Purchases 3,370 Shares of QuidelOrtho (NASDAQ:QDEL) Stock - MarketBeat
QuidelOrtho (NASDAQ:QDEL) CEO Brian Blaser Acquires 10,540 Shares - MarketBeat
QuidelOrtho CFO Busky buys $79k in shares - Investing.com
QuidelOrtho CEO Blaser buys shares worth $248,660 By Investing.com - Investing.com India
QuidelOrtho CEO Blaser buys shares worth $248,660 - Investing.com Australia
Will QuidelOrtho Corporation benefit from rising consumer demand2025 Major Catalysts & High Accuracy Investment Signals - mfd.ru
QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2025 Earnings Call Transcript - Insider Monkey
QuidelOrtho (QDEL) Q3 US$733 Million Loss Reinforces Bearish Profitability Narratives - Sahm
QDEL Q4 Deep Dive: Margin Expansion, R&D Pipeline, and Guidance Disappoints - Finviz
QuidelOrtho (NASDAQ:QDEL) Shares Gap DownHere's Why - MarketBeat
QDEL Stock Slumps On Mixed Wall Street Price Target Revisions After Q4 Report - Stocktwits
UBS Adjusts QuidelOrtho Price Target to $30 From $35, Maintains Neutral Rating - marketscreener.com
QuidelOrtho (NASDAQ:QDEL) Issues FY 2026 Earnings Guidance - MarketBeat
QuidelOrtho Q4 Earnings and Revenues Beat Estimates, Margins Down - Yahoo Finance
Will QuidelOrtho Corporation stock see insider buyingWeekly Market Report & Daily Momentum Trading Reports - mfd.ru
QuidelOrtho Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
QuidelOrtho revenue hits USD 724M in Q4 2025 - Medical Buyer
QuidelOrtho (QDEL) Q4 2025 Earnings Transcript - The Globe and Mail
QuidelOrtho Q4 2025 slides: Revenue beats expectations despite 27% EPS drop - Investing.com Canada
QuidelOrtho Corp (QDEL) Q4 2025 Earnings Call Highlights: Strong Labs Growth Amidst Respiratory Revenue Decline - GuruFocus
What’s next for QuidelOrtho Corporation stockJuly 2025 Volume & High Accuracy Investment Entry Signals - mfd.ru
Quidelortho Corporation Azioni (QDEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):